摘要
目的评价替莫唑胺治疗复发性脑恶性胶质瘤的疗效及安全性。方法 38例复发的恶性胶质瘤患者给予单药替莫唑胺100-200mg/m2,连续口服5d,28d为一周期。所有患者至少接受两个疗程治疗。替莫唑胺化疗后以头颅MRI判断疗效,并记录相关治疗反应。结果中位随访时间8.5个月。8例患者的肿瘤明显缩小,PR率为21.05%;13例患者肿瘤稳定,SD率为34.24%。中位无进展生存期为5.4个月;17例(44.74%)患者无进展生存期超过6个月;1年生存率23.68%(9/38)。替莫唑胺主要不良反应为恶心、呕吐、乏力和骨髓抑制等。结论口服替莫唑胺对恶性复发性胶质瘤患者安全有效。
Objective To evaluate the efficacy and adverse effects of temozolomide in the treatment of recurrent glioma.Methods Thirty-eight patients with recurrent glioma were treated with temozolomide in a dose of 100-200 mg/m2 once a day for 5 days.A treatment cycle was 28 days and each patient received at least two cycles of treatment.The efficacy was evaluated by MRI examination after chemotherapy.Results Median follow-up time was 8.5 months.The partial response rate was 21.05%(8/38),stable disease rate was 34.24%(13/38).The median time for disease progression-free survival was 5.4 months.Seventeen(44.74%) patients were progression-free survival more than 6 months.One-year survival rate was 23.68%.There were no severe temozolomide-related toxicities.The major adverse effects of temozolomide were nausea,vomiting,baldness,acratia and bone marrow depression.Conclusion Treating recurrent gliomas with temozolomide is effective and safe with less adverse effects.
出处
《江苏医药》
CAS
CSCD
北大核心
2012年第7期788-790,共3页
Jiangsu Medical Journal